Evolus, Inc. $EOLS Stock Holdings Trimmed by Renaissance Technologies LLC

Renaissance Technologies LLC decreased its holdings in Evolus, Inc. (NASDAQ:EOLS) by 57.6% in the 1st quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 339,025 shares of the company’s stock after selling 460,875 shares during the quarter. Renaissance Technologies LLC’s holdings in Evolus were worth $1,393,000 as of its most recent filing with the SEC.

A number of other large investors also recently modified their holdings of the business. Larson Financial Group LLC raised its stake in shares of Evolus by 136.6% during the fourth quarter. Larson Financial Group LLC now owns 4,914 shares of the company’s stock valued at $33,000 after purchasing an additional 2,837 shares in the last quarter. Meeder Asset Management Inc. acquired a new stake in Evolus in the fourth quarter worth about $34,000. Wexford Capital LP bought a new position in Evolus in the 3rd quarter valued at about $37,000. Aquatic Capital Management LLC bought a new position in Evolus in the 3rd quarter valued at about $48,000. Finally, State of Wyoming acquired a new position in Evolus during the 4th quarter valued at about $63,000. 90.69% of the stock is owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

EOLS has been the topic of a number of recent analyst reports. Weiss Ratings upgraded shares of Evolus from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 15th. Wall Street Zen upgraded shares of Evolus from a “hold” rating to a “buy” rating in a research note on Saturday, August 8th. Finally, BTIG Research reissued a “buy” rating and set a $13.00 target price on shares of Evolus in a report on Wednesday, June 17th. Four investment analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $14.50.

Evolus Price Performance

EOLS stock opened at $8.12 on Thursday. The firm has a market cap of $536.33 million, a PE ratio of -15.62 and a beta of 1.35. Evolus, Inc. has a 12 month low of $3.86 and a 12 month high of $8.43. The firm has a 50 day simple moving average of $6.61 and a 200 day simple moving average of $5.61.

Evolus Company Profile

Evolus, Inc is a specialty pharmaceutical company focused on medical aesthetics. Headquartered in Newport Beach, California, Evolus develops and commercializes products designed to enhance facial appearance through minimally invasive procedures. Since its founding in 2017, the company has positioned itself in the fast-growing aesthetic market by partnering with leading manufacturers and leveraging clinical expertise to bring innovative injectables to practitioners and patients.

The company’s flagship offering, Jeuveau (prabotulinumtoxinA-xvfs), is a neuromodulator approved by the U.S.